My NCBISign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 81

    1.

    The role of Herceptin in early breast cancer.

    Subramanian A, Mokbel K.

    Int Semin Surg Oncol. 2008 Apr 28;5:9.PMID: 18442393 [PubMed - in process]Related articlesFree article

    2.

    Anti-HER2 treatment and breast cancer: state of the art, recent patents, and new strategies.

    Daniele L, Sapino A.

    Recent Pat Anticancer Drug Discov. 2009 Jan;4(1):9-18. Review.PMID: 19149684 [PubMed - indexed for MEDLINE]Related articles

    3.

    Darpp-32 and its truncated variant t-Darpp have antagonistic effects on breast cancer cell growth and herceptin resistance.

    Gu L, Waliany S, Kane SE.

    PLoS One. 2009 Jul 13;4(7):e6220.PMID: 19593441 [PubMed - indexed for MEDLINE]Related articlesFree article

    4.

    Upregulated HSP27 in human breast cancer cells reduces Herceptin susceptibility by increasing Her2 protein stability.

    Kang SH, Kang KW, Kim KH, Kwon B, Kim SK, Lee HY, Kong SY, Lee ES, Jang SG, Yoo BC.

    BMC Cancer. 2008 Oct 4;8:286.PMID: 18834540 [PubMed - indexed for MEDLINE]Related articlesFree article

    5.

    [Monoclonal antibodies and breast cancer. Current therapeutic progress]

    Collignon J, Gennigens C, Rorive A, Coucke P, Lifrange E, Maweja S, Fillet G, Jerusalem G.

    Rev Med Liege. 2009 May-Jun;64(5-6):279-83. French. PMID: 19642459 [PubMed - indexed for MEDLINE]Related articles

    6.

    Her2-positive breast cancer: herceptin and beyond.

    Dean-Colomb W, Esteva FJ.

    Eur J Cancer. 2008 Dec;44(18):2806-12. Epub 2008 Nov 18. Review.PMID: 19022660 [PubMed - indexed for MEDLINE]Related articles

    7.

    The co-delivery of paclitaxel and Herceptin using cationic micellar nanoparticles.

    Lee AL, Wang Y, Cheng HY, Pervaiz S, Yang YY.

    Biomaterials. 2009 Feb;30(5):919-27. Epub 2008 Nov 29.PMID: 19042015 [PubMed - indexed for MEDLINE]Related articles

    8.

    Targeted therapies in breast cancer: established drugs and recent developments.

    Fischgräbe J, Wülfing P.

    Curr Clin Pharmacol. 2008 May;3(2):85-98. Review.PMID: 18690883 [PubMed - indexed for MEDLINE]Related articles

    9.

    Improvement of sensitivity to tamoxifen in estrogen receptor-positive and Herceptin-resistant breast cancer cells.

    Chen B, Wang Y, Kane SE, Chen S.

    J Mol Endocrinol. 2008 Nov;41(5):367-77. Epub 2008 Sep 3.PMID: 18768663 [PubMed - indexed for MEDLINE]Related articlesFree article

    10.

    Optimizing outcomes in HER2-positive breast cancer: the molecular rationale.

    Esteva FJ, Pusztai L.

    Oncology (Williston Park). 2005 Nov;19(13 Suppl 5):5-16. Review.PMID: 19364051 [PubMed - indexed for MEDLINE]Related articles

    11.

    Hidden HER-2/neu-positive breast cancer: how to maximize detection.

    Carney WP.

    IDrugs. 2009 Apr;12(4):238-42. Review.PMID: 19350468 [PubMed - indexed for MEDLINE]Related articles

    12.

    Development of resistance to targeted therapies transforms the clinically associated molecular profile subtype of breast tumor xenografts.

    Creighton CJ, Massarweh S, Huang S, Tsimelzon A, Hilsenbeck SG, Osborne CK, Shou J, Malorni L, Schiff R.

    Cancer Res. 2008 Sep 15;68(18):7493-501.PMID: 18794137 [PubMed - indexed for MEDLINE]Related articlesFree article

    13.

    EGFR/HER2 in breast cancer: a biological approach for molecular diagnosis and therapy.

    Milanezi F, Carvalho S, Schmitt FC.

    Expert Rev Mol Diagn. 2008 Jul;8(4):417-34. Review.PMID: 18598224 [PubMed - indexed for MEDLINE]Related articles

    14.

    Neural stem cells as a novel platform for tumor-specific delivery of therapeutic antibodies.

    Frank RT, Edmiston M, Kendall SE, Najbauer J, Cheung CW, Kassa T, Metz MZ, Kim SU, Glackin CA, Wu AM, Yazaki PJ, Aboody KS.

    PLoS One. 2009 Dec 15;4(12):e8314.PMID: 20016813 [PubMed - in process]Related articlesFree article

    15.

    Clinical use of selective estrogen receptor modulators and down regulators with the main focus on breast cancer.

    Baumann CK, Castiglione-Gertsch M.

    Minerva Ginecol. 2009 Dec;61(6):517-39.PMID: 19942839 [PubMed - in process]Related articles

    16.

    Suppression of HER2/HER3-mediated growth of breast cancer cells with combinations of GDC-0941 PI3K inhibitor, trastuzumab, and pertuzumab.

    Yao E, Zhou W, Lee-Hoeflich ST, Truong T, Haverty PM, Eastham-Anderson J, Lewin-Koh N, Gunter B, Belvin M, Murray LJ, Friedman LS, Sliwkowski MX, Hoeflich KP.

    Clin Cancer Res. 2009 Jun 15;15(12):4147-56. Epub 2009 Jun 9.PMID: 19509167 [PubMed - indexed for MEDLINE]Related articles

    17.

    Bisphosphonates as adjuvant therapy for breast cancer.

    Burkinshaw R, Coleman R.

    Womens Health (Lond Engl). 2006 Jan;2(1):115-26.PMID: 19803932 [PubMed - in process]Related articles

    18.

    FoxM1 is a downstream target and marker of HER2 overexpression in breast cancer.

    Francis RE, Myatt SS, Krol J, Hartman J, Peck B, McGovern UB, Wang J, Guest SK, Filipovic A, Gojis O, Palmieri C, Peston D, Shousha S, Yu Q, Sicinski P, Coombes RC, Lam EW.

    Int J Oncol. 2009 Jul;35(1):57-68.PMID: 19513552 [PubMed - indexed for MEDLINE]Related articles

    19.

    Carcinosarcoma of the breast: two case reports and review of the literature.

    Esses KM, Hagmaier RM, Blanchard SA, Lazarchick JJ, Riker AI.

    Cases J. 2009 Jan 6;2(1):15.PMID: 19126225 [PubMed - in process]Related articlesFree article

    20.

    The role of HER2 in early breast cancer metastasis and the origins of resistance to HER2-targeted therapies.

    Freudenberg JA, Wang Q, Katsumata M, Drebin J, Nagatomo I, Greene MI.

    Exp Mol Pathol. 2009 Aug;87(1):1-11. Epub 2009 May 18. Review.PMID: 19450579 [PubMed - indexed for MEDLINE]Related articles

    Display Settings:

    Format
    Items per page
    Sort by

    Send to:

    Choose Destination

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity

    You are here: NCBI > Literature > PubMed
    Write to the Help Desk